HER2(human epidermal growth factor receptor 2) -positive metastatic breast cancer in Russia

Trial Identifier: D133HR00027
Sponsor: AstraZeneca
Start Date: May 2023
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Barnaul, Russia
Russia Belgorod, Russia
Russia Chelyabinsk, Russia
Russia Grozniy, Russia
Russia Irkutsk, Russia
Russia Kaluga, Russia
Russia Kchabarovsk, Russia
Russia Khanty-Mansiysk, Russia
Russia Kommunarka, Russia
Russia Kostroma, Russia
Russia Krasnodar, Russia
Russia Krasnoyarsk, Russia
Russia Moscow, Russia
Russia Perm, Russia
Russia Pyatigorsk, Russia
Russia Ryazan, Russia
Russia Sakhalin, Russia
Russia Saransk, Russia
Russia Sochi, Russia
Russia Surgut, Russia
Russia Tomsk, Russia
Russia Tver, Russia
Russia Ufa, Russia
Russia Ulan-Ude, Russia
Russia Vladivostok, Russia
Russia Volgograd, Russia
Russia Yaroslavl, Russia